MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Zentalis Pharmaceuticals Inc

Chiusa

1.65 7.84

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.52

Massimo

1.65

Metriche Chiave

By Trading Economics

Entrata

21M

-27M

Margine di Profitto

-176.706

Dipendenti

166

EBITDA

9.7M

-36M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+335.71% upside

Dividendi

By Dow Jones

Utili prossimi

10 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

12M

112M

Apertura precedente

-6.19

Chiusura precedente

1.65

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Zentalis Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 ott 2025, 23:30 UTC

Azioni calde

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 ott 2025, 21:21 UTC

Utili

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 ott 2025, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 ott 2025, 23:40 UTC

Discorsi di Mercato

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 ott 2025, 23:39 UTC

Discorsi di Mercato

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 ott 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 ott 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 ott 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 ott 2025, 23:00 UTC

Discorsi di Mercato

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 ott 2025, 22:54 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Scales's JV Buyout Lauded by Bull -- Market Talk

2 ott 2025, 22:54 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Forex and Fixed Income Roundup: Market Talk

2 ott 2025, 22:46 UTC

Discorsi di Mercato

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 ott 2025, 22:46 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

2 ott 2025, 21:17 UTC

Acquisizioni, Fusioni, Takeovers

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 ott 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Energy & Utilities Roundup: Market Talk

2 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

2 ott 2025, 20:49 UTC

Acquisizioni, Fusioni, Takeovers

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 ott 2025, 20:00 UTC

Acquisizioni, Fusioni, Takeovers

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 ott 2025, 19:20 UTC

Discorsi di Mercato

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 ott 2025, 19:10 UTC

Discorsi di Mercato

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 ott 2025, 19:04 UTC

Discorsi di Mercato

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 ott 2025, 18:45 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 ott 2025, 18:45 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 ott 2025, 18:44 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 ott 2025, 18:44 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 ott 2025, 18:44 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 ott 2025, 18:43 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Confronto tra pari

Modifica del prezzo

Zentalis Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

335.71% in crescita

Previsioni per 12 mesi

Media 6.71 USD  335.71%

Alto 10 USD

Basso 4 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zentalis Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

8 ratings

4

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.23 / 1.45Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Weak Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat